CRO start­up Vial scores $67M Se­ries B led by Gen­er­al Cat­a­lyst

Vial, a CRO spe­cial­iz­ing in of­fer­ing clin­i­cal tri­al ser­vices to biotech com­pa­nies, raised $67 mil­lion in a new round of fund­ing, bring­ing its to­tal mon­ey raised to $100 mil­lion.

The San Fran­cis­co-based com­pa­ny’s Se­ries B round was led by Gen­er­al Cat­a­lyst and sup­port­ed oth­ers such as By­ers Cap­i­tal and Box­Group.

Vial co-founder and CEO Si­mon Burns said the com­pa­ny will use the fund­ing to ex­pand its clin­i­cal op­er­a­tions and strat­e­gy teams in the US and across the Eu­ro­pean Union and Asia-Pa­cif­ic in or­der to sup­port its clients glob­al­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.